重组活化凝血因子 VII 在心脏手术中用于有效治疗严重难治性出血。
Use of recombinant activated factor VII in cardiac surgery for an effective treatment of severe intractable bleeding.
作者信息
Vanek Tomas, Straka Zbynek, Hrabak Jakub, Jares Martin, Brucek Peter Jan, Votava Jan
机构信息
Department of Cardiac Surgery, 3rd Medical School of Charles University, Kralovske Vinohrady University Hospital, Prague, Czech Republic..
出版信息
Jpn Heart J. 2004 Sep;45(5):855-60. doi: 10.1536/jhj.45.855.
Experience gained with administration of supranormal-therapeutic doses (90 microg/kg) of recombinant activated factor VII in 7 cardiac surgery patients is presented. The patients were given recombinant activated factor VII postoperatively for intractable bleeding, 5 of them after surgical revision. Administration of recombinant activated factor VII was associated with significant reduction in blood loss (P < 0.05) and shortening of INR and aPTT in laboratory tests. None of the patients needed reoperation. Administration of recombinant activated factor VII proved highly effective in management of massive hemorrhage in cardiac surgery.
本文介绍了7例心脏手术患者接受超治疗剂量（90微克/千克）重组活化因子VII治疗的经验。这些患者术后因难治性出血接受重组活化因子VII治疗，其中5例在手术修复后使用。重组活化因子VII的使用与失血量显著减少（P < 0.05）以及实验室检查中INR和aPTT缩短相关。所有患者均无需再次手术。重组活化因子VII在心脏手术大出血的管理中被证明非常有效。
Zotero 插件